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Background: The development of safe and efﬁcacious
vaccines against pathogens like malaria, HIV and TB and
the induction of protective immune responses in popula-
tions with impaired immunity such as the elderly remain
major challenges. Adjuvantation of puriﬁed vaccine antigens
with well-characterized and potent immune stimulators is
designed to achieve these goals. In particular, new adjuvants
need to be rationally developed, extensively characterised
and systematically tested preclinically and in clinical trials
to satisfy a risk/beneﬁt requirement.
Methods: Over the past two decades GSK Biologicals has
developed an Adjuvant Systems (AS) platform - formulation
of classical adjuvants (aluminium salts, oil in water emul-
sions, liposomes) with immunomodulators (MPL, QS21).
AS families have been created, that formulated with the
selected antigen(s) are designed to enhance the immune
response to the targeted pathogen and/or in the target
population.
Results: Adjuvant Systems to be used in combination
with selected antigens have been designed to stimulate the
immune system in speciﬁc and selected ways by promoting
the recruitment of antigen presenting cells and inﬂuenc-
ing the pattern of cytokines produced during interactions
between innate and adaptive immune systems. In most
cases this results in signiﬁcantly better antibody responses.
Certain AS-antigen combinations can selectively drive T-
cell polarization and thus generate persistent cellular and
humoral responses critical for enhanced protection against
the targeted pathogen. Extensive preclinical and clinical
testing has lead to the development of AS-based candi-
date vaccines for malaria (RTS,S), HSV, H5N1 prepandemic
inﬂuenza and licensed vaccines for HBV and cervical cancer
prevention (HPV) formulated with novel adjuvant technol-
ogy.
Conclusion: Clinical studies of AS-containing vaccines
have shown the beneﬁt of adjuvantation, including an
improved vaccine efﬁcacy and/or, better immunogenicity,
and in some cases, allowing signiﬁcant antigen sparing while
maintaining an acceptable safety proﬁle in healthy children,
adults, elderly and in certain high risk populations.
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Background: The GlaxoSmithKline, oral live-attenuated
human rotavirus vaccine RIX4414 RotarixTM) was shown to be
highly immunogenic. A phase III, randomized, double-blind,
placebo-controlled study(NCT00139347-e-Track444563) was
conducted in Latin America to assess the effect of RotarixTM
on the immunogenicity of co-administered oral polio vac-
cine(OPV).
Methods: 6568 healthy infants aged 6—12 weeks were
enrolled to receive two doses of RIX4414 (RIX4414-OPV
group:N = 4376) or placebo (Placebo-OPV:N = 2192) accord-
ing to a 0,1—2 month schedule, administered concomitantly
with Dose1 and Dose2 of routine vaccines including oral
poliovirus vaccines (OPV), according to recommended local
national immunization guidelines. For the immunogenicity
subset for OPV (N = 900) seroprotection rates for anti-polio
types1,2,3 antibodies were determined at 1 month post-
Dose3 of routine pediatric vaccination(virus neutralization
assay, cut-off≥8ED50). Of these, a subset of infants received
an additional OPV dose at birth.
Results: No signiﬁcant difference in anti-polio1,2,3 sero-
protection rates was observed at 1 month post-Dose3 of OPV
between RIX4414-OPV and Placebo-OPV groups.
Conclusions: Co-administration of RotarixTM with OPV
does not interfere with the immune response to OPV. This is
of importance in considering the inclusion of RV vaccination
into UMV programs in countries where OPV is still used.
doi:10.1016/j.ijid.2008.05.375
